Skip to main content
. 2022 Oct 3;13:992731. doi: 10.3389/fphar.2022.992731

TABLE 2.

Baseline characteristics of the study population.

Study ID Study arm Sample Age, year Sex, male FEV1 reversibility % Nasal polyposis history Former smoker Allergic condition
Bacharier et al., 2021 Dupilumab 100–200 mg q2w 273 8.9 ± 1.7 175 (64.1) 21.56 ± 22.43
Placebo 135 8.9 ± 1.6 87 (64.4) 15.63 ± 16.33
Castro et al., 2018, Castro et al., 2020, Corren et al., 2019, Corren et al., 2021 Dupilumab 300 mg q2w 633 47.7 ± 15.6 239 (37.8) 26.29 ± 21.73 145 (22.9) 116 (18.3) 524 (82.8)
Placebo 321 48.2 ± 14.7 103 (32.1) 25.73 ± 17.65 80 (24.9) 67 (20.9) 266 (82.9)
Dupilumab 200 mg q2w 631 47.9 ± 15.3 244 (38.7) 27.39 ± 22.79 141 (22.3) 126 (20.0) 509 (80.7)
Placebo 317 48.2 ± 15.6 119 (37.5) 25.06 ± 18.76 73 (23.0) 59 (18.6) 266 (83.9)
Laidlaw et al., 2021 and Bachert et al., 2020 Dupilumab 300 mg q2w 258 34.78 ± 16.01 210 (49.1) 428 (100)
Placebo 170
Rape et al., 2018 Dupilumab 300 mg q2w 103 51.9 ± 12.5 41 (40) 33 (32) 24 (23) 10 (10)
Placebo 107 50.7 ± 12.8 42 (39) 38 (36) 17 (16) 10 (9)
Tohda et al., 2020 Dupilumab 300 mg q2w 41 47.2 ± 18.2 13 (31.7) 20.11 ± 17.54 8 (19.5) 4 (9.8) 36 (87.8)
Placebo 17 51.4 ± 12.9 5 (29.4) 21.55 ± 17.95 7 (41.2) 6 (35.3) 13 (76.5)
Dupilumab 200 mg q2w 37 49 ± 16 19 (51.4) 20.63 ± 19.64 12 (32.4) 10 (27.0) 33 (89.2)
Placebo 19 47.1 ± 16.9 8 (42.1) 21 ± 11.44 2 (10.5) 6 (31.6) 18 (94.7)
Wechsler et al., 2021 Dupilumab 300 mg 75 51.3 ± 12.7 34 (45) 13.32 ± 11.76 14 (19) 66 (88)
Placebo 74 47 ± 11.4 27 (36) 15.58 ± 15.84 17 (9) 67 (91)
Weinstein et al. 2018- with PAR Dupilumab 300 mg q2w 84 45 ± 13.2 34 (40.5) 20 (23.8) 53 (63.9)
Dupilumab 200 mg q2w 73 46.6 ± 14.6 24 (32.9) 17 (23.3) 54 (75)
Placebo 84 47.9 ± 12.9 34 (40.5) 18 (21.4) 59 (71.1)
Weinstein et al. 2018- without PAR Dupilumab 300 mg q2w 43 48.8 ± 11.5 8 (18.6) 9 (20.9) 21 (51.2)
Dupilumab 200 mg q2w 52 55.6 ± 10.5 14 (26.9) 9 (17.3) 29 (55.8)
Placebo 56 51.9 ± 13.2 12 (21.4) 13 (23.2) 30 (56.6)
Wenzel et al., 2013 Dupilumab 300 mg q2w 52 37.8 ± 13.2 26 (50)
Placebo 52 41.6 ± 13.1 26 (50)
Wenzel et al., 2016 Dupilumab 200 mg q4w 154 47.9 ± 13.1 67 (43·5) 21 (13·9) 34 (22·2) 100 (66·2)
Dupilumab 300 mg q4w 157 47.9 ± 13.1 57 (36·3) 31 (20·0) 38 (24·2) 99 (63·9)
Dupilumab 200 mg q2w 157 51 ± 13.4 54 (36·0) 25 (16·8) 32 (21·3) 99 (66·4)
Dupilumab 300 mg q2w 150 47.5 ± 12.4 54 (34·4) 30 (19·5) 36 (22·9) 94 (61·0)
Placebo 157 49 ± 12.7 54 (34·2) 18 (11·7) 34 (21·5) 102 (66·2)

PAR; perennial allergic rhinitis, FEV1; forced expiratory volume in 1 s. Data are reported as mean ± standard deviation or number (percentage).